Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
2.050
-0.410 (-16.67%)
Jan 21, 2025, 4:00 PM EST - Market closed
Company Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.
Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.
The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer.
Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Marker Therapeutics, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Juan Vera |
Contact Details
Address: 9350 Kirby Drive, Suite 300 Houston, Texas 77054 United States | |
| Phone | 713 400 6400 |
| Website | markertherapeutics.com |
Stock Details
| Ticker Symbol | MRKR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001094038 |
| CUSIP Number | 57055L107 |
| ISIN Number | US57055L2060 |
| Employer ID | 88-0277072 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Juan F. Vera M.D. | Co-Founder, Chief Executive Officer, President, Treasurer, Secretary and Director |
| Elizabeth Donnelly | Director of Administration |
| Dr. Maria-Bernadette Madel | Director of Corporate Operations and External Communications |
| Edmund Cheung | Vice President of Human Resources |
| Dr. Monic Stuart M.D. | Chief Medical Officer |
| Patricia Allison | Head of Clinical Operations |
| Mary Newman Ph.D. | Head of Regulatory Affairs |
| Dr. Robert Z. Florkiewicz Sr. | Senior Director of Molecular Biology and Virology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 17, 2025 | EFFECT | Notice of Effectiveness |
| Jan 17, 2025 | 424B3 | Prospectus |
| Jan 13, 2025 | PRE 14A | Other preliminary proxy statements |
| Jan 10, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Dec 30, 2024 | D | Notice of Exempt Offering of Securities |
| Dec 23, 2024 | 8-K | Current Report |
| Dec 23, 2024 | SCHEDULE 13D/A | Filing |
| Dec 19, 2024 | 8-K | Current Report |
| Dec 17, 2024 | 8-K | Current Report |
| Dec 6, 2024 | EFFECT | Notice of Effectiveness |